Corvus Pharmaceuticals, Inc.
CRVSDrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
Aug 6, 2026
2dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
CRVS Earnings Report
EPS Est: $-0.17 | FQ end 2026-06 | Call: 2026-08-06 15:00:00
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How CRVS's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Soquelitinib | Phase 3 | Peripheral T-Cell Lymphoma, Not Otherwise Specified | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Corvus Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Corvus Pharmaceuticals, Inc.'s (CRVS) pipeline across Phase 3. Its lead program is Soquelitinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Corvus Pharmaceuticals, Inc.'s next FDA catalyst?→
Corvus Pharmaceuticals, Inc.'s (CRVS) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CRVS biotech catalysts?→
Add CRVS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Corvus Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.